Literature DB >> 15620479

Structure-activity relations of water-in-oil vaccine formulations and induced antigen-specific antibody responses.

Theo Jansen1, Marij P M Hofmans, Marc J G Theelen, Virgil E J C Schijns.   

Abstract

Water-in-oil (W/O) emulsions are known as most effective adjuvants to generate high and durable antibody responses to vaccine antigens following a single immunization. However, their structural requirements remain poorly understood. Here we addressed the significance of certain pharmaceutical characteristics including water/oil ratios--ranging from 60/40 to 30/70 (w/w(%))--droplet size and type of oil, i.e. non-metabolizable (mineral oil) versus metabolizable (Miglyol 840). Stability of emulsions was accomplished by the use of a polymeric emulsifier. Distinct W/O emulsions were formulated with inactivated (i) infectious bronchitis virus (iIBV) and Newcastle disease virus (iNDV), and evaluated in immunized chickens for magnitude and duration of in vivo antiviral antibody formation and local reactions. A high mineral oil content proved most effective for antibody response formation. In general, a larger droplet size evoked higher antibody responses for both oil types. Inoculum residues proved lower using biodegradable Miglyol, when compared to mineral oil, for all emulsion variants. Especially water-to-oil ratio and droplet size may provide useful parameters for improving (antiviral) antibody production by W/O emulsions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15620479     DOI: 10.1016/j.vaccine.2004.08.023

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Computed tomography-guided screening of surfactant effect on blood circulation time of emulsions: application to the design of an emulsion formulation for paclitaxel.

Authors:  Eun-Hye Lee; Soon-Seok Hong; So Hee Kim; Mi-Kyung Lee; Joon Seok Lim; Soo-Jeong Lim
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

2.  Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

Authors:  Christopher B Fox; Susan L Baldwin; Malcolm S Duthie; Steven G Reed; Thomas S Vedvick
Journal:  Vaccine       Date:  2011-09-09       Impact factor: 3.641

3.  Effect of alum co-adjuvantation of oil adjuvant vaccine on emulsion stability and immune responses against haemorhagic septicaemia in mice.

Authors:  Sujeet Kumar; Vinod Kumar Chaturvedi; Bablu Kumar; Pankaj Kumar; Sudha Rani Somarajan; Anil Kumar Mishra; Bhaskar Sharma
Journal:  Iran J Microbiol       Date:  2015-04

4.  Effects of Chicken Interferon Gamma on Newcastle Disease Virus Vaccine Immunogenicity.

Authors:  Stivalis Cardenas-Garcia; Robert P Dunwoody; Valerie Marcano; Diego G Diel; Robert J Williams; Robert M Gogal; Corrie C Brown; Patti J Miller; Claudio L Afonso
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

5.  Evolution of H9N2 avian influenza virus in embryonated chicken eggs with or without homologous vaccine antibodies.

Authors:  Haiyun Jin; Wan Wang; Xueqin Yang; Hailong Su; Jiawen Fan; Rui Zhu; Shifeng Wang; Huoying Shi; Xiufan Liu
Journal:  BMC Vet Res       Date:  2018-03-06       Impact factor: 2.741

6.  Comparative safety and efficacy of two bivalent vaccines containing Newcastle disease LaSota and avian influenza H9N2 Sidrap isolate formulated with different oil adjuvants.

Authors:  Jossie Intan Cahyani; Sitarina Widyarini; Michael Haryadi Wibowo
Journal:  Vet World       Date:  2020-11-24

Review 7.  Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines.

Authors:  Huub F J Savelkoul; Valerie A Ferro; Marius M Strioga; Virgil E J C Schijns
Journal:  Vaccines (Basel)       Date:  2015-03-05

8.  Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy.

Authors:  Christopher B Fox; Lucien Barnes V; Tara Evers; James D Chesko; Thomas S Vedvick; Rhea N Coler; Steven G Reed; Susan L Baldwin
Journal:  Influenza Other Respir Viruses       Date:  2012-11-05       Impact factor: 4.380

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.